Rajesh Nair, MD
Hematology & Oncology · Springfield, MONPI 1609072347
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,039 of the $2,286 with a category attached, or 89.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,172, more than ten times the $93 reported in 2019.
Across 102 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$389
- Johnson & Johnson$225
- E.r. Squibb & Sons, L.L.C.$183
- Sanofi$182
- Pfizer$179
- Bristol Myers Squibb$176
- plus $952 from 21 others
Across 21 payments — averaging $5486.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$82K
- Bristol Myers Squibb$30K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Novartis$500
What the payments were for
- Food & beverage$2,03989%
- Education$24711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $389 |
| Johnson & Johnson | 9 | $225 |
| E.r. Squibb & Sons, L.L.C. | 12 | $183 |
| Sanofi | 3 | $182 |
| Pfizer | 8 | $179 |
| Bristol Myers Squibb | 10 | $176 |
| Amgen | 2 | $112 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| GSK | 4 | $89 |
| Eisai Inc. | 4 | $67 |
| Tempus AI, Inc | 3 | $65 |
| Gilead | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| AstraZeneca | 2 | $41 |
| Acrotech Biopharma Inc. | 3 | $40 |
| Karyopharm Therapeutics Inc. | 1 | $40 |
| Array Biopharma Inc | 2 | $37 |
| Merck | 2 | $37 |
| Astellas Pharma US Inc | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $29 |
| Exelixis Inc. | 1 | $26 |
| Pharmaessentia USA Corporation | 1 | $24 |
| Lilly USA, LLC | 1 | $18 |
| AbbVie | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$150
How this compares
$2,286 in reported general payments places this provider in the 55th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 69 | $802,285 |
| XtandiEnzalutamide | 59 | $784,616 |
| PomalystPomalidomide | 37 | $690,309 |
| RevlimidLenalidomide | 23 | $439,091 |
| ImbruvicaIbrutinib | 24 | $393,241 |
| TibsovoIvosidenib | 12 | $373,980 |
| IbrancePalbociclib | 23 | $360,673 |
| BrukinsaZanubrutinib | 28 | $289,621 |
| CabometyxCabozantinib S-Malate | 11 | $286,137 |
| SprycelDasatinib | 11 | $195,141 |
| Lenalidomide | 13 | $129,654 |
| PromactaEltrombopag Olamine | 18 | $95,221 |
| Abiraterone Acetate | 47 | $86,269 |
| EliquisApixaban | 91 | $55,328 |
| GleostineLomustine | 12 | $8,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $183 | $885,45048 claims |
| AstraZenecaCalquence | $41 | $802,28569 claims |
| Astellas Pharma US IncXtandi | $32 | $784,61659 claims |
| Bristol Myers SquibbRevlimid | $176 | $439,09123 claims |
| PfizerIbrance, Eliquis | $179 | $416,001114 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $13 | $393,24124 claims |
| Exelixis Inc.Cabometyx | $26 | $286,13711 claims |
| NovartisPromacta | $389 | $95,22118 claims |
| GSKTrelegy Ellipta | $89 | $8,30014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Springfield
- Raymond LobinsSpringfield$22K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.